Intellia Therapeutics

Intellia Therapeutics is a genome editing company focused on developing therapeutics utilizing a biological tool known as Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9). This is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. The company utilizes its CRISPR/Cas9 platform across two areas: in vivo applications, in which CRISPR/Cas9 is therapy, delivered to target cells within the body; and ex vivo applications, in which CRISPR/Cas9 creates therapy of engineered human cells.
  • TickerNTLA
  • ISINUS45826J1051
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for N...

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis. This investigati...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancem...

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics and SparingVision Announce Strategic Collaborati...

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targetsIntellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targe...

 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for N...

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis. This investigati...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancem...

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics and SparingVision Announce Strategic Collaborati...

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targetsIntellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targe...

 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for N...

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis. This investigati...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancem...

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics and SparingVision Announce Strategic Collaborati...

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targetsIntellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targe...

 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for N...

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis. This investigati...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancem...

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics and SparingVision Announce Strategic Collaborati...

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targetsIntellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targe...

 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for N...

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis. This investigati...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancem...

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress First preclinical data demonstrating Intellia’s allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a more efficient multiplex gene editing approach for engineered cell therapies as compared to electroporation Achieved durable production of normal human alpha-1 antitrypsin protein levels and reduction of endogenous ...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
NTLA Intellia Therap... (Health Care)

Intellia Therapeutics and SparingVision Announce Strategic Collaborati...

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise Intellia will grant SparingVision exclusive rights to its leading in vivo CRISPR/Cas9 technology for the development of ocular therapies directed to three targetsIntellia will receive an equity stake in SparingVision and will have an option to obtain exclusive US commercialization rights for ocular therapies for two targe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch